Paracervical block with ropivacaine for pain relief in second trimester medical abortion - a double blind placebo controlled randomized trial

2025-524599-52-03 · tracked via the Priya Life Science EU tracker

Sponsor

Karolinska Institutet

Sponsor type

Educational Institution

Therapeutic area

Female Urogenital Diseases and Pregnancy Complications

Decision date

17/07/2026

Enrollment target

132

Sites

Sweden

Condition studied

abortion

Investigational medicinal product(s)

ROPIVACAINEELECTROLYTES

Every trial of Ropivacaine across our registers →

Eligibility

Age group

18-64 years

Sex

Female

Primary endpoint

Primary outcome is maximum pain score on a VAS (measured in millimeters) during the procedure

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524599-52-03 on CTIS ↗ ← All trials in the EU